Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.13 +0.27 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
A wave of market-relevant news fueled an active trading session on Wall Street Tuesday, with large-cap indices falling due to sharp declines in tech and energy stocks, while small-caps outperformed,... 
Via Benzinga
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson’s Medtech Segment Shines With Impressive Q3 Growth
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19. 
Via Talk Markets
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
Johnson & Johnson reported third-quarter earnings with adjusted EPS of $2.42, surpassing expectations. Sales rose 5.2% to $22.47B. J&J updated its 2024 adjusted EPS guidance, lowering it slightly to... 
Via Benzinga
Johnson & Johnson Earnings Top; Dow Giant Works Toward Buy Point
J&J stock edged higher early Tuesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
Wall Street mood has become circumspect as traders gear up to receive a slew of earnings reports this week amid the market’s record run. The Nasdaq Composite has been a laggard among the major averages... 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
Market Whales and Their Recent Bets on JNJ Options
Via Benzinga
What Analysts Are Saying About Johnson & Johnson Stock
Via Benzinga
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
The stock market has been on a two-year strong run and the extended rally has begun to stir valuation concerns. 
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
3 Mega-Cap Stocks For Long-Term Dividend Growth
Mega cap stocks have the size and economies of scale to pay long-term dividends to shareholders. 
Via Talk Markets
Insights Into Johnson &amp; Johnson's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s... 
Via Benzinga
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's stagnant performance. 
Via Benzinga
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive. 
Via MarketBeat
Columbus Day: Is Stock Market Open Today?
Investors should brace for a busy week with earnings reports from major companies. 
Via Benzinga
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations. 
Via The Motley Fool
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
Stocks Extend Weekly Win Streaks To 5
Wall Street enjoyed healthy gains to close out both the day and week. 
Via Talk Markets
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Completes Acquisition of V-Wave
From Johnson & Johnson
Via Business Wire
1 Vanguard Index Fund Could Turn $500 Per Month Into a $968,400 Portfolio That Pays $16,000 in Annual Dividend Income
Workers with median earnings can build sizable portfolios that pay hefty amounts of passive income in retirement. 
Via The Motley Fool
Should Investors Consider High Yield Dividend Stocks?
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But are high-yield stocks always the best route for income-focused investors?... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.